Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2004 Jan 26;90(2):304-5.
doi: 10.1038/sj.bjc.6601303.

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

J S Kloover  1 , M A den Bakker, H Gelderblom, J P van Meerbeeck
Affiliations
Case Reports

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

J S Kloover et al. Br J Cancer. .

Abstract

Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8: 611–614 - PubMed
    1. Dye D, Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. BMJ 280: 1353 - PMC - PubMed
    1. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle delection for drug formulation. Eur J Cancer 37: 1590–1598 - PubMed
    1. Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35: 1114–1117 - PubMed
    1. Koppler H, Heymanns J, Weide R (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24: 283–285 - PubMed

Publication types

MeSH terms